These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20053770)

  • 1. Meeting report on the second targeted tumor therapies.
    Bachran C; Fuchs H
    Mol Cancer Ther; 2010 Jan; 9(1):17-23. PubMed ID: 20053770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recombinant immunotoxin for cancer therapy: current status and prospective].
    Nagata S
    Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):540-6. PubMed ID: 11268658
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates.
    Sharkey RM; Sausville EA; Goldenberg DM
    Cancer Res; 2003 Nov; 63(22):8069-71. PubMed ID: 14633741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latest discoveries and trends in translational cancer research: highlights of the 2008 Annual Meeting of the American Association for Cancer Research.
    Cho WC
    Technol Cancer Res Treat; 2008 Aug; 7(4):269-77. PubMed ID: 18642965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
    De Santis F; Del Vecchio M; Castagnoli L; De Braud F; Di Cosimo S; Franceschini D; Fucà G; Hiscott J; Malmberg KJ; McGranahan N; Pietrantonio F; Rivoltini L; Sangaletti S; Tagliabue E; Tripodo C; Vernieri C; Zitvogel L; Pupa SM; Di Nicola M
    Cytokine Growth Factor Rev; 2018 Dec; 44():1-10. PubMed ID: 30393044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based therapeutics in oncology.
    Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
    MacDonald GC; Glover N
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
    Plane G
    IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in anticancer antibody-drug conjugates and immunotoxins.
    Dosio F; Stella B; Cerioni S; Gastaldi D; Arpicco S
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):35-65. PubMed ID: 23477784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthrax fusion protein therapy of cancer.
    Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH
    Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotoxins: selection of cell-surface antigens and their corresponding monoclonal antibodies.
    Bjorn MJ; Villemez CL
    Cancer Treat Res; 1988; 37():255-77. PubMed ID: 2908629
    [No Abstract]   [Full Text] [Related]  

  • 20. Marine and freshwater toxins.
    Hungerford JM;
    J AOAC Int; 2006; 89(1):248-69. PubMed ID: 16512256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.